Natalizumab discontinuation after PML risk stratification: Outcome from a shared and informed decision

Multiple Sclerosis Journal

Volumn 18, Issue 8, 2012, Pages 1193-1196

  Tur, Carmen ^a   Tintoré, Mar ^a   Vidal Jordana, Angela ^a   Castilló, Joaquín ^a   Galán, Ingrid ^a   Río, Jordi ^a   Arrambide, Georgina ^a   Comabella, Manuel ^a   Arévalo, Ma Jesús ^a   Horno, Rosalía ^a   Vicente, Ma José ^a   Caminero, Ana ^a   Nos, Carlos ^a   Sastre Garriga, Jaume ^a   Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

JC virus; multiple sclerosis; natalizumab; progressive multifocal leukoencephalopathy

Indexed keywords

NATALIZUMAB;

ADULT; ARTICLE; CLINICAL DECISION MAKING; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; REMISSION; RISK ASSESSMENT; RISK FACTOR; SEROLOGY;

EID: 84864132082     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512439238     Document Type: Article

References (10)

1. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003 ; 348: 15-23
2. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
3. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 911-923
4. Kappos L, Bates D, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol. 2007 ; 6: 431-441
5. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011 ; 10: 745-758
6. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol. 2003 ; 71: 115-123
7. Sandrock A, Hotermans C, Richman S. Risk stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab treatment duration, and anti-JCF antibody status. Neurology. 2011 ; 76 (suppl 4). A248
8. Biogen Idec and Elan Pharmaceuticals. JCV antibody program in patients with relapsing multiple sclerosis receiving or considering treatment with Tysabri: STRATIFY-2. http://clinicaltrials.gov/ct2/show/NCT01070836, 2011. [Accessed August 4, 2011].
9. O'Connor AM, Wennberg JE, Legare F, et al. Toward the 'tipping point': decision aids and informed patient choice. Health Aff (Millwood). 2007 ; 26: 716-725
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452